Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
J Neurol
; 270(5): 2531-2546, 2023 May.
Article
in En
| MEDLINE
| ID: mdl-36735057
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Muscular Atrophy, Spinal
/
Spinal Muscular Atrophies of Childhood
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Neurol
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: